Search

Your search keyword '"bioactive fish peptide"' showing total 2 results
Start Over Descriptor "bioactive fish peptide" Topic fish proteins
2 results on '"bioactive fish peptide"'

1. Effects of a Cod Protein Hydrolysate Supplement on Symptoms, Gut Integrity Markers and Fecal Fermentation in Patients with Irritable Bowel Syndrome.

Author

Dale HF, Jensen C, Hausken T, Valeur J, Hoff DAL, and Lied GA

Subjects
Animals, Diet Records, Double-Blind Method, Fatty Acids, Volatile chemistry, Feces chemistry, Female, Fermentation, Humans, Hydrolysis, Male, Dietary Supplements, Fish Proteins chemistry, Fish Proteins therapeutic use, Gadiformes, Irritable Bowel Syndrome drug therapy
Abstract

Peptides from fish may beneficially affect several metabolic outcomes, including gut health and inflammation. The effect of fish peptides in subjects with irritable bowel syndrome (IBS) has not previously been investigated, hence this study aimed to evaluate the effect of a cod protein hydrolysate (CPH) supplement on symptom severity, gut integrity markers and fecal fermentation in IBS-patients. A double-blind, randomized parallel-intervention with six weeks of supplementation with 2.5 g CPH ( n = 13) or placebo ( n = 15) was conducted. The outcomes were evaluated at baseline and the end of the study. The primary outcomes were symptom severity evaluated by the IBS severity scoring system (IBS-SSS) and quality of life. The secondary outcomes included gut integrity markers and pro-inflammatory cytokines in serum, fecal fermentation measured by concentration of short-chain fatty acids (SCFAs) and fecal calprotectin. The groups were comparable at baseline. The total IBS-SSS-scores were reduced in both the CPH-group (298 ± 69 to 236 ± 106, p = 0.081) and the placebo-group (295 ± 107 to 202 ± 103, p = 0.005), but the end of study-scores did not differ ( p = 0.395). The concentrations of serum markers and SCFAs did not change for any of the groups. The baseline measures for the whole group showed that the total SCFA concentrations were inversely correlated with the total IBS-SSS-score ( r = -0.527, p = 0.004). Our study showed that a low dose of CPH taken daily by IBS-patients for six weeks did not affect symptom severity, gut integrity markers or fecal fermentation when compared to the placebo group., Competing Interests: The authors declare no conflicts of interest.

Published
2019
Full Text
View/download PDF

2. Effects of a Cod Protein Hydrolysate Supplement on Symptoms, Gut Integrity Markers and Fecal Fermentation in Patients with Irritable Bowel Syndrome

Author

Ingeborg Brønstad, Jan Gunnar Hatlebakk, Jørgen Valeur, Trygve Hausken, Dag Arne Lihaug Hoff, Hanna Fjeldheim Dale, Caroline Jensen, and Gülen Arslan Lied

Subjects
Fish Proteins, Male, 0301 basic medicine, medicine.medical_specialty, short-chain fatty acids, Inflammation, lcsh:TX341-641, Placebo, Gastroenterology, Article, Hydrolysate, bioactive fish peptide, Feces, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Internal medicine, low-grade inflammation, Animals, Humans, Medicine, In patient, Irritable bowel syndrome, irritable bowel syndrome, 030109 nutrition & dietetics, Nutrition and Dietetics, business.industry, Hydrolysis, gut integrity markers, Fatty Acids, Volatile, medicine.disease, Diet Records, Gadiformes, Dietary Supplements, Fermentation, Female, 030211 gastroenterology & hepatology, medicine.symptom, Calprotectin, business, lcsh:Nutrition. Foods and food supply, Food Science
Abstract

Peptides from fish may beneficially affect several metabolic outcomes, including gut health and inflammation. The effect of fish peptides in subjects with irritable bowel syndrome (IBS) has not previously been investigated, hence this study aimed to evaluate the effect of a cod protein hydrolysate (CPH) supplement on symptom severity, gut integrity markers and fecal fermentation in IBS-patients. A double-blind, randomized parallel-intervention with six weeks of supplementation with 2.5 g CPH (n = 13) or placebo (n = 15) was conducted. The outcomes were evaluated at baseline and the end of the study. The primary outcomes were symptom severity evaluated by the IBS severity scoring system (IBS-SSS) and quality of life. The secondary outcomes included gut integrity markers and pro-inflammatory cytokines in serum, fecal fermentation measured by concentration of short-chain fatty acids (SCFAs) and fecal calprotectin. The groups were comparable at baseline. The total IBS-SSS-scores were reduced in both the CPH-group (298 &plusmn, 69 to 236 &plusmn, 106, p = 0.081) and the placebo-group (295 &plusmn, 107 to 202 &plusmn, 103, p = 0.005), but the end of study-scores did not differ (p = 0.395). The concentrations of serum markers and SCFAs did not change for any of the groups. The baseline measures for the whole group showed that the total SCFA concentrations were inversely correlated with the total IBS-SSS-score (r = &minus, 0.527, p = 0.004). Our study showed that a low dose of CPH taken daily by IBS-patients for six weeks did not affect symptom severity, gut integrity markers or fecal fermentation when compared to the placebo group.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results